Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis
Open Access
- 9 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1485609
Abstract
Background: To compare the efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).Methods: We searched databases, including PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and major international conferences, to identify comparative randomized controlled trials (RCTs) for the first-line treatment of patients with nasopharyngeal carcinoma who have metastasis or recurrence from inception to March 1, 2024. Then, we conducted a Bayesian network meta-analysis and systematic review of RCTs that met the specified inclusion criteria. By calculating the surface under the cumulative ranking curve (SUCRA) for each treatment, we determined their relative advantage: the higher the SUCRA score, the more likely that treatment is to be the optimal choice.Results: Seven RCTs were included, which involved 1495 patients who received 8 different treatment regimens. Overall, programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy could be the optimal treatment for patients with RM-NPC. Chemotherapy combined with radiotherapy has a tendency to improve progression-free survival and overall survival. The safety assessment showed no significant difference in the incidence of grade 3 or higher adverse events between any two treatments. Tislelizumab, combined with the standard first-line chemotherapy regimen, appeared to confer the best progression-free survival (SUCRA = 83.16%), overall survival (SUCRA = 83.16%), and objective response rate (SUCRA = 89%).Conclusions: Systematic reviews and network meta-analyses integrate evidence from multiple studies, which enables clinicians to make more informed treatment decisions based on comprehensive comparative efficacy and safety data. For patients with RM-NPC, the combination of tislelizumab and chemotherapy is the optimal first-line treatment.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023491570, identifier CRD42023491570.Keywords
This publication has 29 references indexed in Scilit:
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal CarcinomaJAMA, 2023
- Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)Cancer Cell, 2023
- Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trialAnnals of Oncology, 2022
- Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trialESMO Open, 2021
- Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†Annals of Oncology, 2021
- Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal CarcinomaJAMA Oncology, 2020
- Management of locally recurrent nasopharyngeal carcinomaCancer Treatment Reviews, 2019
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJournal of Clinical Epidemiology, 2011
- Evaluating novel agent effects in multiple‐treatments meta‐regressionStatistics in Medicine, 2010
- Assessing the convergence of Markov Chain Monte Carlo methods: An example from evaluation of diagnostic tests in absence of a gold standardPreventive Veterinary Medicine, 2007